Avenue Therapeutics, which is a Fortress Biotech spinoff developing an IV formulation of the opioid tramadol, raised $33 million by offering 5.5 million shares at $6, the midpoint of the $5 to $7 lowered range. Avenue Therapeutics plans to list on the Nasdaq under the symbol ATXI. Oppenheimer & Co. acted as a lead manager on the deal.
